Stimulation with a class A CpG oligonucleotide enhances resistance to infection with feline viruses from five different families

Veterinary Research

Volumn 43, Issue 1, 2012, Pages

  Robert Tissot, Céline ^a   Rüegger, Vera L ^a   Cattori, Valentino ^a   Meli, Marina L ^a   Riond, Barbara ^a   Moore, Peter F ^b   Engels, Monika ^a   Franchini, Marco ^a   Hofmann Lehmann, Regina ^a   Lutz, Hans ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALICIVIRIDAE; CORONAVIRIDAE; CORONAVIRUS; FELIDAE; FELIS CATUS; HERPESVIRIDAE; ORTHOMYXOVIRIDAE; PARVOVIRIDAE; PARVOVIRUS; RETROVIRIDAE;

CPG ODN 2216; MYXOVIRUS RESISTANCE PROTEIN; OLIGODEOXYRIBONUCLEOTIDE;

ANIMAL; ANIMAL DISEASE; ARTICLE; CAT; CAT DISEASE; CELL LINE; CELL PROLIFERATION; CLASSIFICATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; INNATE IMMUNITY; MALE; METABOLISM; MONONUCLEAR CELL; RANDOMIZATION; REAL TIME POLYMERASE CHAIN REACTION; SPECIES DIFFERENCE; VIROLOGY; VIRUS; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; CAT DISEASES; CATS; CELL LINE; CELL PROLIFERATION; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; IMMUNITY, INNATE; LEUKOCYTES, MONONUCLEAR; MALE; MYXOVIRUS RESISTANCE PROTEINS; OLIGODEOXYRIBONUCLEOTIDES; RANDOM ALLOCATION; REAL-TIME POLYMERASE CHAIN REACTION; SPECIES SPECIFICITY; VIRUS DISEASES; VIRUS REPLICATION; VIRUSES;

EID: 84872082271     PISSN: 09284249     EISSN: 12979716     Source Type: Journal    
DOI: 10.1186/1297-9716-43-60     Document Type: Article

References (89)

1. Common virus infections in cats, before and after being placed in shelters, with emphasis on feline enteric coronavirus. Pedersen NC, Sato R, Foley JE, Poland AM, J Feline Med Surg 2004 6 83 88 10.1016/j.jfms.2003.08.008 15123152 (Pubitemid 38482211)
2. Epidemiologic evaluation of multiple respiratory pathogens in cats in animal shelters. Bannasch MJ, Foley JE, J Feline Med Surg 2005 7 109 119 10.1016/j.jfms.2004.07.004 15771947 (Pubitemid 40353127)
3. The challenge for the next generation of feline calicivirus vaccines. Radford AD, Dawson S, Coyne KP, Porter CJ, Gaskell RM, Vet Microbiol 2006 117 14 18 10.1016/j.vetmic.2006.04.004 16698199 (Pubitemid 44332845)
4. Recognition of microorganisms and activation of the immune response. Medzhitov R, Nature 2007 449 819 826 10.1038/nature06246 17943118 (Pubitemid 47598622)
5. A Toll-like receptor recognizes bacterial DNA. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S, Nature 2000 408 740 745 10.1038/35047123 11130078 (Pubitemid 32015992)
6. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G, J Immunol 2002 168 4531 4537 11970999 (Pubitemid 34441357)
7. Toll-like receptor control of the adaptive immune responses. Iwasaki A, Medzhitov R, Nat Immunol 2004 5 987 995 10.1038/ni1112 15454922 (Pubitemid 41057715)
8. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Sparwasser T, Koch ES, Vabulas RM, Heeg K, Lipford GB, Ellwart JW, Wagner H, Eur J Immunol 1998 28 2045 2054 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8 9645386 (Pubitemid 28271721)
9. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Hartmann G, Weiner GJ, Krieg AM, Proc Natl Acad Sci U S A 1999 96 9305 9310 10.1073/pnas.96.16.9305 10430938 (Pubitemid 29374750)
10. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM, Proc Natl Acad Sci U S A 1996 93 2879 2883 10.1073/pnas.93.7.2879 8610135 (Pubitemid 26116242)
11. Type I interferon is required to mount an adaptive response to immunostimulatory DNA. Van Uden JH, Tran CH, Carson DA, Raz E, Eur J Immunol 2001 31 3281 3290 10.1002/1521-4141(200111)31:11<3281::AID-IMMU3281>3.0. CO;2-0 11745345 (Pubitemid 33100520)
12. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G, Eur J Immunol 2001 31 2154 2163 10.1002/1521-4141(200107)31:7<2154::AID- IMMU2154>3.0.CO;2-U 11449369 (Pubitemid 32640732)
13. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B, Schreiber RD, Hertzog P, Smyth MJ, J Immunol 2007 178 7540 7549 17548588 (Pubitemid 46898022)
14. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. Santini SM, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T, Belardelli F, J Exp Med 2000 191 1777 1788 10.1084/jem.191.10.1777 10811870 (Pubitemid 30331574)
15. Plasmacytoid dendritic cells, antigen, and CpG-C license human B cells for plasma cell differentiation and immunoglobulin production in the absence of T-cell help. Poeck H, Wagner M, Battiany J, Rothenfusser S, Wellisch D, Hornung V, Jahrsdorfer B, Giese T, Endres S, Hartmann G, Blood 2004 103 3058 3064 10.1182/blood-2003-08-2972 15070685 (Pubitemid 38451681)
16. The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. Rogge L, D'Ambrosio D, Biffi M, Penna G, Minetti LJ, Presky DH, Adorini L, Sinigaglia F, J Immunol 1998 161 6567 6574 9862683 (Pubitemid 28562196)
17. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Nguyen KB, Watford WT, Salomon R, Hofmann SR, Pien GC, Morinobu A, Gadina M, O'Shea JJ, Biron CA, Science 2002 297 2063 2066 10.1126/science.1074900 12242445
18. Interferon-inducible antiviral effectors. Sadler AJ, Williams BR, Nat Rev Immunol 2008 8 559 568 10.1038/nri2314 18575461 (Pubitemid 351913674)
19. Interferon, Mx, and viral countermeasures. Haller O, Kochs G, Weber F, Cytokine Growth Factor Rev 2007 18 425 433 10.1016/j.cytogfr.2007.06.001 17683972 (Pubitemid 47302821)
20. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM, Eur J Immunol 2004 34 251 262 10.1002/eji.200324032 14971051 (Pubitemid 38111541)
21. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. Ballas ZK, Rasmussen WL, Krieg AM, J Immunol 1996 157 1840 1845 8757300 (Pubitemid 126449654)
22. CpG motifs in bacterial DNA trigger direct B-cell activation. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM, Nature 1995 374 546 549 10.1038/374546a0 7700380
23. Mechanism and function of a newly identified CpG DNA motif in human primary B cells. Hartmann G, Krieg AM, J Immunol 2000 164 944 953 10623843
24. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH, Davis HL, Krieg AM, J Immunol 2000 164 1617 1624 10640783 (Pubitemid 30067282)
25. CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Rankin R, Pontarollo R, Ioannou X, Krieg AM, Hecker R, Babiuk LA, van Drunen Littel-van den Hurk S, Antisense Nucleic Acid Drug Dev 2001 11 333 340 10.1089/108729001753231713 11763350 (Pubitemid 33070092)
26. Response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides. Kamstrup S, Verthelyi D, Klinman DM, Vet Microbiol 2001 78 353 362 10.1016/S0378-1135(00)00300-X 11182501 (Pubitemid 32162922)
27. Monocytes are required for optimum in vitro stimulation of bovine peripheral blood mononuclear cells by non-methylated CpG motifs. Pontarollo RA, Rankin R, Babiuk LA, Godson DL, Griebel PJ, Hecker R, Krieg AM, van Drunen Littel-van den Hurk S, Vet Immunol Immunopathol 2002 84 43 59 10.1016/S0165-2427(01)00379-8 11825597 (Pubitemid 34083578)
28. Bovine and ovine blood mononuclear leukocytes differ markedly in innate immune responses induced by Class A and Class B CpG-oligodeoxynucleotide. Mena A, Nichani AK, Popowych Y, Ioannou XP, Godson DL, Mutwiri GK, Hecker R, Babiuk LA, Griebel P, Oligonucleotides 2003 13 245 259 10.1089/154545703322460621 15000839 (Pubitemid 37428816)
29. Identification of CpG oligodeoxynucleotide sequences that induce IFN-gamma production in canine peripheral blood mononuclear cells. Kurata K, Iwata A, Masuda K, Sakaguchi M, Ohno K, Tsujimoto H, Vet Immunol Immunopathol 2004 102 441 450 10.1016/j.vetimm.2004.08.004 15541797 (Pubitemid 39487236)
30. Type-A CpG oligonucleotides activate exclusively porcine natural interferon-producing cells to secrete interferon-alpha, tumour necrosis factor-alpha and interleukin-12. Guzylack-Piriou L, Balmelli C, McCullough KC, Summerfield A, Immunology 2004 112 28 37 10.1111/j.1365-2567.2004.01856.x 15096181 (Pubitemid 38609819)
31. Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. Abel K, Wang Y, Fritts L, Sanchez E, Chung E, Fitzgerald-Bocarsly P, Krieg AM, Miller CJ, Clin Diagn Lab Immunol 2005 12 606 621 15879022 (Pubitemid 41184721)
32. CpG oligodeoxynucleotide induction of antiviral effector molecules in sheep. Nichani AK, Kaushik RS, Mena A, Popowych Y, Dent D, Townsend HG, Mutwiri G, Hecker R, Babiuk LA, Griebel PJ, Cell Immunol 2004 227 24 37 10.1016/j.cellimm.2004.01.004 15051512 (Pubitemid 38393726)
33. In vivo immunostimulatory effects of CpG oligodeoxynucleotide in cattle and sheep. Nichani AK, Mena A, Popowych Y, Dent D, Townsend HG, Mutwiri GK, Hecker R, Babiuk LA, Griebel PJ, Vet Immunol Immunopathol 2004 98 17 29 10.1016/j.vetimm.2003.10.001 15127838 (Pubitemid 38209986)
34. Identification of cytosine-phosphorothioate-guanine oligodeoxynucleotide sequences that induce interferon-gamma production in feline immune cells. Satoh R, Kotake M, Takano T, Motokawa K, Gemma T, Watanabe R, Arai S, Hohdatsu T, Microbiol Immunol 2011 55 184 190 10.1111/j.1348-0421.2010.00298.x 21204950
35. CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation. Wernette CM, Smith BF, Barksdale ZL, Hecker R, Baker HJ, Vet Immunol Immunopathol 2002 84 223 236 10.1016/S0165-2427(01)00410-X 11777536 (Pubitemid 34037118)
36. Adjuvanted rush immunotherapy using CpG oligodeoxynucleotides in experimental feline allergic asthma. Reinero CR, Cohn LA, Delgado C, Spinka CM, Schooley EK, DeClue AE, Vet Immunol Immunopathol 2008 121 241 250 10.1016/j.vetimm.2007.09.013 17981343 (Pubitemid 351163398)
37. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Hartmann G, Battiany J, Poeck H, Wagner M, Kerkmann M, Lubenow N, Rothenfusser S, Endres S, Eur J Immunol 2003 33 1633 1641 10.1002/eji.200323813 12778481 (Pubitemid 36790424)
38. Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions. Marshall JD, Fearon K, Abbate C, Subramanian S, Yee P, Gregorio J, Coffman RL, Van Nest G, J Leukoc Biol 2003 73 781 792 10.1189/jlb.1202630 12773511 (Pubitemid 38040457)
39. A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. Samulowitz U, Weber M, Weeratna R, Uhlmann E, Noll B, Krieg AM, Vollmer J, Oligonucleotides 2010 20 93 101 10.1089/oli.2009.0210 20384481
40. Therapeutic applications of CpG-containing oligodeoxynucleotides. Klinman DM, Antisense Nucleic Acid Drug Dev 1998 8 181 184 10.1089/oli.1.1998.8.181 9593061 (Pubitemid 28223342)
41. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. Krieg AM, Love-Homan L, Yi AK, Harty JT, J Immunol 1998 161 2428 2434 9725240 (Pubitemid 28397058)
42. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM, J Immunol 1999 162 2291 2298 9973506 (Pubitemid 29288853)
43. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. Weighardt H, Feterowski C, Veit M, Rump M, Wagner H, Holzmann B, J Immunol 2000 165 4537 4543 11035094
44. CpG oligodeoxynucleotides stimulate protective innate immunity against pulmonary Klebsiella infection. Deng JC, Moore TA, Newstead MW, Zeng X, Krieg AM, Standiford TJ, J Immunol 2004 173 5148 5155 15470059 (Pubitemid 39402952)
45. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, Wagner H, Heeg K, J Immunol 1998 160 3627 3630 9558060 (Pubitemid 28176060)
46. CpG oligonucleotides can prophylactically immunize against Th2-mediated schistosome egg-induced pathology by an IL-12-independent mechanism. Chiaramonte MG, Hesse M, Cheever AW, Wynn TA, J Immunol 2000 164 973 985 10623847 (Pubitemid 30043725)
47. Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Gramzinski RA, Doolan DL, Sedegah M, Davis HL, Krieg AM, Hoffman SL, Infect Immun 2001 69 1643 1649 10.1128/IAI.69.3.1643-1649.2001 11179339 (Pubitemid 32187621)
48. A protective role of locally administered immunostimulatory CpG oligodeoxynucleotide in a mouse model of genital herpes infection. Harandi AM, Eriksson K, Holmgren J, J Virol 2003 77 953 962 10.1128/JVI.77.2.953-962.2003 12502811 (Pubitemid 36055517)
49. CpG oligodeoxynucleotides protect newborn mice from a lethal challenge with the neurotropic Tacaribe arenavirus. Pedras-Vasconcelos JA, Goucher D, Puig M, Tonelli LH, Wang V, Ito S, Verthelyi D, J Immunol 2006 176 4940 4949 16585590
50. Protection of Balb/c mice against infection with FMDV by immunostimulation with CpG oligonucleotides. Kamstrup S, Frimann TH, Barfoed AM, Antiviral Res 2006 72 42 48 10.1016/j.antiviral.2006.03.010 16678920 (Pubitemid 44308444)
51. CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. Rees DG, Gates AJ, Green M, Eastaugh L, Lukaszewski RA, Griffin KF, Krieg AM, Titball RW, Antiviral Res 2005 65 87 95 10.1016/j.antiviral.2004.10.004 15708635 (Pubitemid 40222285)
52. Stimulation of innate immune responses by CpG oligodeoxynucleotide in newborn lambs can reduce bovine herpesvirus-1 shedding. Nichani AK, Mena A, Kaushik RS, Mutwiri GK, Townsend HG, Hecker R, Krieg AM, Babiuk LA, Griebel PJ, Oligonucleotides 2006 16 58 67 10.1089/oli.2006.16.58 16584295
53. Subcutaneous, but not intratracheal administration of the TLR9 agonist, CpG DNA transiently reduces parainfluenza-3 virus shedding in newborn lambs. Nichani AK, Dar MA, Mirakhur KK, Krieg AM, Booth JS, Townsend HG, Potter AA, Babiuk LA, Mutwiri GK, Comp Immunol Microbiol Infect Dis 2010 33 111 e117 10.1016/j.cimid.2010.06.003 20619456
54. In vivo transmission studies of ' Candidatus Mycoplasma turicensis' in the domestic cat. Museux K, Boretti FS, Willi B, Riond B, Hoelzle K, Hoelzle LE, Wittenbrink MM, Tasker S, Wengi N, Reusch CE, Lutz H, Hofmann-Lehmann R, Vet Res 2009 40 45 10.1051/vetres/2009028 19505421
55. Housing and care of laboratory cats: from requirements to practice. Geret C, Riond B, Cattori V, Meli M, Hofmann-Lehmann R, Lutz H, Schweizer Archiv für Tierheilkunde 2011 153 157 164 10.1024/0036-7281/a000175
56. The role of in vitro-induced lymphocyte apoptosis in feline immunodeficiency virus infection: correlation with different markers of disease progression. Holznagel E, Hofmann-Lehmann R, Leutenegger CM, Allenspach K, Huettner S, Forster U, Niederer E, Joller H, Willett BJ, Hummel U, Rossi GL, Schüpbach J, Lutz H, J Virol 1998 72 9025 9033 9765447 (Pubitemid 28471846)
57. Evaluation of a novel haematology analyser for use with feline blood. Weissenbacher S, Riond B, Hofmann-Lehmann R, Lutz H, Vet J 2011 187 381 387 10.1016/j.tvjl.2010.01.005 20133174
58. The innate antiviral immune system of the cat: Molecular tools for the measurement of its state of activation. Robert-Tissot C, Ruegger VL, Cattori V, Meli ML, Riond B, Gomes-Keller MA, Vogtlin A, Wittig B, Juhls C, Hofmann-Lehmann R, Lutz H, Vet Immunol Immunopathol 2011 143 269 281 10.1016/j.vetimm.2011.06. 005 21719112
59. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F, Genome Biol 2002 3 ESEARCH0034 12184808
60. Quantitative TaqMan real-time PCR assays for gene expression normalisation in feline tissues. Kessler Y, Helfer-Hungerbuehler AK, Cattori V, Meli ML, Zellweger B, Ossent P, Riond B, Reusch CE, Lutz H, Hofmann-Lehmann R, BMC Mol Biol 2009 10 106 10.1186/1471-2199-10-106 20003366
61. In vitro and in vivo detection of Mx gene products in bovine cells following stimulation with alpha/beta interferon and viruses. Muller-Doblies D, Ackermann M, Metzler A, Clin Diagn Lab Immunol 2002 9 1192 1199 12414749 (Pubitemid 35283279)
62. Measurement of antiviral activity induced by interferons alpha, beta, and gamma. Vogel SN, Friedman RM, Hogan MM, Curr Protoc Immunol 2001 Chapter 6 nit 69
63. Quantitation of feline leukaemia virus viral and proviral loads by TaqMan real-time polymerase chain reaction. Tandon R, Cattori V, Gomes-Keller MA, Meli ML, Golder MC, Lutz H, Hofmann-Lehmann R, J Virol Methods 2005 130 124 132 10.1016/j.jviromet.2005.06.017 16054243 (Pubitemid 41596993)
64. Activity of feline interferon-omega after ocular or oral administration in cats as indicated by Mx protein expression in conjunctival and white blood cells. Bracklein T, Theise S, Metzler A, Spiess BM, Richter M, Am J Vet Res 2006 67 1025 1032 10.2460/ajvr.67.6.1025 16740097 (Pubitemid 43971120)
65. Relative sensitivities of viruses to different species of interferon. Stewart WE 2nd, Scott WD, Sulkin SE, J Virol 1969 4 147 153 4308914
66. Inhibitory effects of recombinant feline interferon on the replication of feline enteropathogenic virusesin vitro. Mochizuki M, Nakatani H, Yoshida M, Vet Microbiol 1994 39 145 152 10.1016/0378-1135(94)90095-7 7515537 (Pubitemid 24107606)
67. Effect of type I interferons on the expression of feline leukaemia virus. Collado VM, Gomez-Lucia E, Tejerizo G, Miro G, Escolar E, Martin S, Domenech A, Vet Microbiol 2007 123 180 186 10.1016/j.vetmic.2007.03.008 17507184 (Pubitemid 46898727)
68. Innate immune responses induced by classes of CpG oligodeoxynucleotides in ovine lymph node and blood mononuclear cells. Booth JS, Nichani AK, Benjamin P, Dar A, Krieg AM, Babiuk LA, Mutwiri GK, Vet Immunol Immunopathol 2007 115 24 34 10.1016/j.vetimm.2006.09.008 17067685 (Pubitemid 44908671)
69. Immunity and immunopathology to viruses: what decides the outcome? Rouse BT, Sehrawat S, Nat Rev Immunol 2010 10 514 526 10.1038/nri2802 20577268
70. Virus-specific interferon action. Protection of newborn Mx carriers against lethal infection with influenza virus. Haller O, Arnheiter H, Gresser I, Lindenmann J, J Exp Med 1981 154 199 203 10.1084/jem.154.1.199 6166723 (Pubitemid 11079817)
71. The interferon-alpha and interleukin-10 responses in neonates differ from adults, and their production remains partial throughout the first 18 months of life. Vosters O, Lombard C, Andre F, Sana G, Sokal EM, Smets F, Clin Exp Immunol 2010 162 494 499 10.1111/j.1365-2249.2010.04267.x 20964643
72. Blood plasmacytoid dendritic cell responses to CpG oligodeoxynucleotides are impaired in human newborns. De Wit D, Olislagers V, Goriely S, Vermeulen F, Wagner H, Goldman M, Willems F, Blood 2004 103 1030 1032 14504106 (Pubitemid 38129567)
73. Innate immunity of the newborn: basic mechanisms and clinical correlates. Levy O, Nat Rev Immunol 2007 7 379 390 10.1038/nri2075 17457344 (Pubitemid 46674489)
74. T cell development in the fetus and neonate. Wilson CB, Lewis DB, English BK, Adv Exp Med Biol 1991 310 17 27 10.1007/978-1-4615-3838-7-2 1808993
75. Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848. Levy O, Zarember KA, Roy RM, Cywes C, Godowski PJ, Wessels MR, J Immunol 2004 173 4627 4634 15383597 (Pubitemid 39280696)
76. Role of MyD88 in diminished tumor necrosis factor alpha production by newborn mononuclear cells in response to lipopolysaccharide. Yan SR, Qing G, Byers DM, Stadnyk AW, Al-Hertani W, Bortolussi R, Infect Immun 2004 72 1223 1229 10.1128/IAI.72.3.1223-1229.2004 14977922 (Pubitemid 38263739)
77. Innate immune responses induced by CpG oligodeoxyribonucleotide stimulation of ovine blood mononuclear cells. Mena A, Nichani AK, Popowych Y, Godson DL, Dent D, Townsend HG, Mutwiri GK, Hecker R, Babiuk LA, Griebel P, Immunology 2003 110 250 257 10.1046/j.1365-2567.2003.01722.x 14511239 (Pubitemid 37249265)
78. Synergy of CpG oligodeoxynucleotide and double-stranded RNA (poly I:C) on nitric oxide induction in chicken peripheral blood monocytes. He H, Genovese KJ, Nisbet DJ, Kogut MH, Mol Immunol 2007 44 3234 3242 10.1016/j.molimm.2007.01. 034 17339052 (Pubitemid 46610502)
79. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Henry SP, Beattie G, Yeh G, Chappel A, Giclas P, Mortari A, Jagels MA, Kornbrust DJ, Levin AA, Int Immunopharmacol 2002 2 1657 1666 10.1016/S1567-5769(02)00142-X 12469940 (Pubitemid 35284605)
80. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, Zinkernagel R, Aguzzi A, Nat Med 2004 10 187 192 10.1038/nm987 14745443 (Pubitemid 38524890)
81. Feline interferon-omega treatment on canine parvovirus infection. Minagawa T, Ishiwata K, Kajimoto T, Vet Microbiol 1999 69 51 53 10.1016/S0378-1135(99)00087-5 10515269 (Pubitemid 29428136)
82. Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs. Ishiwata K, Minagawa T, Kajimoto T, J Vet Med Sci 1998 60 911 917 10.1292/jvms.60.911 9764403 (Pubitemid 128533523)
83. Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled challenge trial. Martin V, Najbar W, Gueguen S, Grousson D, Eun HM, Lebreux B, Aubert A, Vet Microbiol 2002 89 115 127 10.1016/S0378- 1135(02)00173-6 12243889 (Pubitemid 35247869)
84. Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled field trial. de Mari K, Maynard L, Eun HM, Lebreux B, Vet Rec 2003 152 105 108 10.1136/vr.152.4.105 12572939 (Pubitemid 36305183)
85. Pretreatment with feline interferon omega and the course of subsequent infection with feline herpesvirus in cats. Haid C, Kaps S, Gonczi E, Hassig M, Metzler A, Spiess BM, Richter M, Vet Ophthalmol 2007 10 278 284 10.1111/j.1463-5224.2007.00550.x 17760705 (Pubitemid 47319865)
86. Sensitivity of FCV to recombinant feline interferon (rFeIFN). Ohe K, Takahashi T, Hara D, Hara M, Vet Res Commun 2008 32 167 174 17909979
87. Evaluation of inflammation and immunity in cats with spontaneous parvovirus infection: consequences of recombinant feline interferon-omega administration. Paltrinieri S, Crippa A, Comerio T, Angioletti A, Roccabianca P, Vet Immunol Immunopathol 2007 118 68 74 10.1016/j.vetimm.2007.04.007 17521745 (Pubitemid 46970790)
88. The role of differential expression of human interferon-α genes in antiviral immunity. Genin P, Vaccaro A, Civas A, Cytokine Growth Factor Rev 2009 20 283 295 10.1016/j.cytogfr.2009.07.005 19651532
89. Use of CpG oligodeoxynucleotides as immunoprotective agents. Klinman DM, Expert Opin Biol Ther 2004 4 937 946 10.1517/14712598.4.6.937 15174975 (Pubitemid 38843230)